REMS (Risk Evaluation and Mitigation Strategy)

Deep dive

REMS (Risk Evaluation and Mitigation Strategy): complete reference

Risk Evaluation and Mitigation Strategy (REMS) is an FDA-mandated safety program required for some medications with serious safety concerns. REMS programs can include: medication guide requirements (patient-facing safety information), restricted distribution (only certified prescribers/pharmacies can dispense), patient + provider certification programs, ongoing safety monitoring/reporting, registry enrollment, or controlled administration settings. GLP-1 medications generally do NOT have REMS programs — they have standard FDA labeling with boxed warning for thyroid C-cell tumors but no enrollment requirements. The boxed warning is sufficient safety communication without REMS. Compare with other classes that do have REMS (some opioids, certain biologics, transmucosal fentanyl products). Not having REMS means GLP-1 prescribing has standard prescriber requirements — no special certification needed beyond standard DEA + medical license. Patients don't need to enroll in any registry. Routine pharmacy dispensing applies.

In practice

Some drugs require special doctor certification + patient enrollment в FDA registry before prescribing — that's REMS. GLP-1s don't require this — any licensed prescriber can write them with standard precautions.

Clinical context

GLP-1s don't have REMS. Standard prescribing applies — no enrollment, no certification beyond standard credentialing.